Drug intelligence / Profile preview

SIR0811

Development stage: Preclinical
Lead developer: Sironax
Administration: Oral

Overview

SIR0811 is an undisclosed preclinical-stage therapeutic candidate being developed by Sironax for the treatment of neurodegenerative diseases. The program is part of Sironax's pipeline targeting fundamental biological mechanisms of aging and age-related degeneration, such as dysregulated cell death, chronic inflammation, and energy imbalance. Further details regarding the specific molecular target and modality of SIR0811 remain undisclosed.

Targets

SARM1

Beyond the preview

Go deeper on SIR0811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR0811.

Explore the full profile